Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

We conducted a SNP-based genome-wide association study (GWAS) focused on the high-risk subset of neuroblastoma. As our previous unbiased GWAS showed strong association of common 6p22 SNP alleles with aggressive neuroblastoma, we restricted our analysis here to 397 high-risk cases compared to 2,043 controls. We detected new significant association of six SNPs at 2q35 within the BARD1 locus (Pallelic = 2.35 × 10−9–2.25 × 10−8). We confirmed each SNP association in a second series of 189 high-risk cases and 1,178 controls (Pallelic = 7.90 × 10−7–2.77 × 10−4). We also tested the two most significant SNPs (rs6435862, rs3768716) in two additional independent high-risk neuroblastoma case series, yielding combined allelic odds ratios of 1.68 each (P = 8.65 × 10−18 and 2.74 × 10−16, respectively). We also found significant association with known BARD1 nonsynonymous SNPs. These data show that common variation in BARD1 contributes to the etiology of the aggressive and most clinically relevant subset of human neuroblastoma.

[1]  Laurent Briollais,et al.  SNP-SNP interactions in breast cancer susceptibility , 2006, BMC Cancer.

[2]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[3]  J. Gulcher,et al.  The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland , 2006, PLoS medicine.

[4]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[5]  D. Reich,et al.  Population Structure and Eigenanalysis , 2006, PLoS genetics.

[6]  Heli Nevanlinna,et al.  BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition , 2006, European Journal of Human Genetics.

[7]  F. Berthold,et al.  Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. , 2005, The Lancet. Oncology.

[8]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.

[9]  F. Berthold,et al.  Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[11]  G. Giles,et al.  The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case–control and family analysis , 2009, Breast Cancer Research and Treatment.

[12]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[13]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[14]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[15]  C. Jefford,et al.  Is there more to BARD1 than BRCA1? , 2006, Nature Reviews Cancer.

[16]  D. Stram,et al.  Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[18]  Nazneen Rahman,et al.  Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. , 2008, The New England journal of medicine.

[19]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.